WO2004016810A3 - Verwendung von an mrp4 bindenden substanzen zur diagnose und behandlung von krebserkrankungen - Google Patents

Verwendung von an mrp4 bindenden substanzen zur diagnose und behandlung von krebserkrankungen Download PDF

Info

Publication number
WO2004016810A3
WO2004016810A3 PCT/DE2003/002159 DE0302159W WO2004016810A3 WO 2004016810 A3 WO2004016810 A3 WO 2004016810A3 DE 0302159 W DE0302159 W DE 0302159W WO 2004016810 A3 WO2004016810 A3 WO 2004016810A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrp4
diagnosis
treatment
cancer
binding substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2003/002159
Other languages
English (en)
French (fr)
Other versions
WO2004016810A2 (de
Inventor
Uta Schwidetzky
Christian Pilarsky
Bernd Hinzmann
Thomas Specht
Andre Rosenthal
Rosemarie Lichtner
Edgar Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003250766A priority Critical patent/AU2003250766A1/en
Publication of WO2004016810A2 publication Critical patent/WO2004016810A2/de
Publication of WO2004016810A3 publication Critical patent/WO2004016810A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft Verwendungen von Mrp4 zur Diagnose und Behandlung von Prostata- und/oder Blasen- und/oder Ovartumoren, sowie zum Screenen nach Substanzen für solche Zwecke.
PCT/DE2003/002159 2002-07-26 2003-06-23 Verwendung von an mrp4 bindenden substanzen zur diagnose und behandlung von krebserkrankungen Ceased WO2004016810A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003250766A AU2003250766A1 (en) 2002-07-26 2003-06-23 Use of an mrp4 binding substances for the diagnosis and treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10234901.0 2002-07-26
DE2002134901 DE10234901A1 (de) 2002-07-26 2002-07-26 Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen

Publications (2)

Publication Number Publication Date
WO2004016810A2 WO2004016810A2 (de) 2004-02-26
WO2004016810A3 true WO2004016810A3 (de) 2004-11-11

Family

ID=30128555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/002159 Ceased WO2004016810A2 (de) 2002-07-26 2003-06-23 Verwendung von an mrp4 bindenden substanzen zur diagnose und behandlung von krebserkrankungen

Country Status (3)

Country Link
AU (1) AU2003250766A1 (de)
DE (1) DE10234901A1 (de)
WO (1) WO2004016810A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
EP1784511A4 (de) * 2004-08-13 2009-03-11 Millennium Pharm Inc Gene, zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von prostatakrebs
CN102958941A (zh) * 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051633A2 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002030268A2 (en) * 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1217066A1 (de) * 2000-12-21 2002-06-26 Universiteit Gent Modulierung von transportwirkung einer ATP-bindenden Kassette
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759238B1 (en) * 1999-03-31 2004-07-06 St. Jude Children's Research Hospital Multidrug resistance associated proteins and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051633A2 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002030268A2 (en) * 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1217066A1 (de) * 2000-12-21 2002-06-26 Universiteit Gent Modulierung von transportwirkung einer ATP-bindenden Kassette
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BORST P ET AL: "A family of drug transporters: the multidrug resistance-associated proteins.", JOURNAL OF THE NATIONAL CANCER INSTITUTE. UNITED STATES 16 AUG 2000, vol. 92, no. 16, 16 August 2000 (2000-08-16), pages 1295 - 1302, XP009013640, ISSN: 0027-8874 *
DATABASE GENESEQ [online] 18 April 2002 (2002-04-18), GISH ET AL.: "Detecting a prostate cancer-associated transcript in a cell in a patient, useful for diagnosing prostate cancer or screening modulators of prostate cancer", XP002270644, Database accession no. ABG61820 *
DATABASE GENESEQ [online] EBI; "Human prostate-specific 1st full length cDNA sequence for P510S", XP002270640, Database accession no. AAH93828 *
DATABASE GENESEQ [online] EBI; 19 July 2001 (2001-07-19), XU ET AL.: "Human prostate-specific 1st amino acid sequence for P510S", XP002270639, Database accession no. AAM01179 *
DATABASE GENESEQ [online] EBI; 23 August 2001 (2001-08-23), SCHLEGEL ET AL.: "Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer", XP002270643, Database accession no. ABV25387 *
DATABASE GENESEQ [online] EBI; 4 October 2001 (2001-10-04), XP002270641, Database accession no. AAS63921 *
DATABASE GENESEQ [online] EBI; 4 October 2001 (2001-10-04), XU ET AL., XP002270642, Database accession no. AAU69824 *

Also Published As

Publication number Publication date
DE10234901A1 (de) 2004-02-12
AU2003250766A1 (en) 2004-03-03
WO2004016810A2 (de) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2003008583A3 (en) Novel compositions and methods for cancer
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2006083971A3 (en) Dr5 antibodies and uses thereof
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP2230254A3 (de) Therapeutische anti-igfr1-Antikörper-Kombinationen
WO2007013950A3 (en) Combination therapy of her expressing tumors
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2003087831A3 (en) Proteins involved in breast cancer
EP1587837A3 (de) Epitop sequenzen abgeleited aus prostat specifischen membran antigen (psma)
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
EP2631248A3 (de) Behandlung von Tumoren unter Verwendung eines spezifischen Anti-L1-Antikörpers
WO2003045230A3 (en) Novel compositions and methods for cancer
MXPA03002323A (es) Metodos de diagnostico de cancer colorectal, composiciones y metodos para seleccionar moduladores de cancer colorectal.
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2003057146A3 (en) Novel compositions and methods for cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP